

TOTAL SYNTHESIS OF ANHYDRO LEVUGLANDIN D₂


Bruce S. Levison, Donald B. Miller, Robert G. Salomon*

Department of Chemistry
Case Western Reserve University
Cleveland, Ohio 44106 U.S.A.

Abstract. Total synthesis of anhydro levuglandin D₂ [9-acetyl-8-formyl-5(Z),9(E),11(E)-hepta-decatrienoic acid] confirms the structure assigned to this 9,10-*seco* prostanic acid product from solvent induced rearrangement of the prostaglandin endoperoxide PGH₂ in aqueous solution.

The prostaglandin (PG) endoperoxide PGH₂ (1) is extraordinarily unstable in the aqueous environment of its biosynthesis.¹ Besides the prostaglandins PGE₂ (2) and PGD₂ (3) which were recognized previously as products of this decomposition,¹ two new aldehyde products were recently shown to be formed in about 20% combined yield.² Model studies³ suggested that these new products are levulinaldehyde derivatives which we named levuglandin E₂ (LGE₂, 4) and levuglandin D₂ (LGD₂, 5) because of their respective relationship to E and D prostaglandins by aldol condensation (see scheme I).


Scheme I



In contrast with thromboxanes which are 11,12-*seco* prostanic acids, the E levuglandins are 10,11-*seco* and the D levuglandins are 9,10-*seco* prostanic acids. Since the levuglandins are vinylogous β -hydroxy carbonyl compounds, they readily undergo dehydration affording anhydro derivatives 6 and 7. These dehydration products were both isolated recently.⁴ However, ¹H NMR and mass

spectral data were deemed inadequate for unambiguous distinction between 6 and 7. Therefore, total synthesis was desirable to firmly establish the identities of the E₂ and D₂ levuglandins. A short total synthesis of anhydro LGD₂ (7) is outlined in scheme II.

Scheme II



Our initial plan for construction of the intermediate 11b envisioned Michael addition of vinyl cuprate 10⁵ to the α,β -unsaturated lactone 9a.⁶ However, even in the presence of MgBr₂ (1 equiv) as a Lewis acid catalyst,⁷ treatment of 9a with 10 in Et₂O-THF solution at -78° to 20°C followed by protic quench with 10% aqueous NH₄Cl led to recovery of 9a and formation of 3-*t*-butyldimethylsilyloxyoct-1-ene. Therefore, the more electrophilic Michael acceptor 9b⁸ was prepared by heating a benzene solution of dimethyl acetylenedicarboxylate (8)⁹ in the presence of *p*-toluenesulfonic acid (9 mol %). Treatment of 9b with vinyl cuprate 10 in ether solution at -78° to 20°C followed by protic quench with saturated aqueous NH₄Cl afforded 11a. Decarbomethoxylation of 11a was achieved by heating a solution in DMSO-water 5:1 (v/v) under reflux in the presence of NaCl (1 equiv).¹⁰ The product lactone 11b was lithiated with lithium hexamethyldisilazane in THF at -78°C. Allylation of the lithium enolate 11c with *t*-butyl (Z)-7-bromohept-5-enoate¹¹ (1 equiv) in THF-HMPA 92:8 (v/v) at -40° to -20°C for 1h, followed by quenching with saturated aqueous NH₄Cl provided 12 which possesses the carbon skeleton of LGD₂. The *t*-butyl ester was chosen because of its expected

resistance to the aluminum hydride reduction¹² which is required for adjusting the oxidation level of 12. The key selective reduction was achieved in good yield using lithium di-*i*-butyl-*t*-butylhydridoaluminate in pentane-tetrahydrofuran at -78° to 20°C followed by quenching with methanol and then acetic acid. Note that the final product is the ketoaldehyde 13. The observed lack of overreduction suggests that the initially formed reduction product, a hemiacetal-mixed ketal, is not converted to 13 until the protic quench.

It is interesting that 13 appears to be less prone to dehydration than LGD_2 (5), the corresponding hydroxy acid. Thus, 13 is readily purified and isolated in 67% yield from the key reduction of 12. Treatment with formic acid does promote elimination and concomitant dealkylation of the ester to provide anhydro LGD_2 (7). The ^1H NMR and mass spectra of 7 are identical with those of anhydro LGD_2 obtained by solvent induced decomposition of PGH_2 . These spectra are presented in figures 1 and 2. An E configuration for the 9,10 C=C bond is indicated by the ^1H NMR spectrum of 7




Figure 1. 200 MHz ^1H NMR spectrum of anhydro levuglandin D_2 in CDCl_3 ; inset shows C-10 hydrogen resonance of spectrum in CD_2Cl_2 .




Figure 2. Mass spectrum of anhydro levuglandin D_2 (7).

since only one vinyl proton resonance appears at $\delta > 7.0$. The resonances for two vinyl protons, i.e. those on C₁₀ and C₁₁, would be expected¹³ to appear at $\delta > 7.0$ if the 9,10 C=C bond had the alternative Z configuration.

Acknowledgement: This research was assisted financially by Grant GM-21249 from the Division of General Medical Sciences of the National Institutes of Health.

References and Notes

1. (a) Hamberg, M.; Samuelsson, B. Proc. Nat. Acad. Sci. USA **1973**, *70*, 899. (b) Hamberg, M.; Svensson, J.; Wakabayashi, T.; Samuelsson, B. ibid **1974**, *71*, 345. (c) Nugteren, D.H.; Hazelhof, E. Biochim. Biophys. Acta **1973**, *326*, 448. (d) Raz, A.; Kenig-Wakshal, R.; Schwartzman, M. ibid **1977**, *488*, 322. (e) Nugteren, D.H.; Christ-Hazelhof, E. Adv. Prostaglandin Thromboxane Res. **1980**, *6*, 129.
2. (a) Zagorski, M.G.; Salomon, R.G. J. Am. Chem. Soc. **1982**, *104*, 3498. (b) Salomon, R.G.; Miller, D.B.; Zagorski, M.G.; Coughlin, D.J. ibid **1984**, in press.
3. (a) Salomon, R.G.; Salomon, M.F.; Coughlin, D.J. ibid **1978**, *100*, 660. (b) Salomon, R.G.; Coughlin, D.J. ibid **1979**, *101*, 2761.
4. Miller, D.B.; Lal, K.; Salomon, R.G. ibid **1984**, submitted.
5. Corey, E.J.; Beames, D.J. ibid **1972**, *94*, 7210.
6. Seltzer, S.; Stevens, K.D. J. Org. Chem. **1968**, *33*, 2708.
7. (a) Salomon, R.G.; Miller, D.B.; Raychaudhuri, S.R.; Avasthi, K.; Lal, K. J. Am. Chem. Soc. **1984**, submitted. (d) Yamamoto, Y.; Yamamoto, S.; Yatagai, H.; Ishihara, Y.; Maruyama, K. J. Org. Chem. **1982**, *47*, 119.
8. **9b** shows m.p. 68-70°C, white flakes from Et₂O; ¹H NMR (CDCl₃, 60 MHz) δ 1.70(s,3H), 3.27(s,3H), 3.8(s,3H), 7.84(s,H).
9. (a) Ouali, M.S.; Vaultier, M.; Corrie, R. Synthesis **1977**, 626. (b) Mayring, L.; Severin, T. Chem. Ber. **1981**, *114*, 3863.
10. Krapcho, A.P.; Lovey, A.J. Tetrahedron Lett. **1973**, 957.
11. This bromoester was prepared from 7-tetrahydropyranyloxy-5-heptynoic acid [(a) Martel, J.; Toromanoff, E. German Patent **2,121,361** (1971); Chem. Abstr. **1972**, *76*, 24712d. (b) Corey, E.J.; Sachdev, H.S. J. Am. Chem. Soc. **1972**, *95*, 8483. (c) Martel, J.; Blade-Font, A.; Marie, C.; Vivat, M.; Toromanoff, E.; Buendia, J. Bull. Soc. Chim. Fr. II **1978**, 131] by t-butylation with N,N-dimethylformamide di-t-butylacetal [Widmer, V. Synthesis **1983**, 135], selective hydrolysis of the tetrahydropyranyl acetal with acetic acid in THF [Bernady, K.F.; Floyd, M.B.; Poletto, J.F.; Weiss, M.J. J. Org. Chem. **1979**, *44*, 1438], partial hydrogenation in the presence of palladium on barium sulfate and synthetic quinoline [Cram, D.J.; Allinger, N.L. J. Am. Chem. Soc. **1955**, *78*, 2518] and treatment of the resulting alcohol with PBr₃ in ether solution at 0°-35°C.
12. Greene, T.W. "Protective Groups in Organic Synthesis", John Wiley & Sons, New York, p. 317 (1981).
13. Ananthasubramanian, L.; Carey, S.T.; Nair, M.S.R. Tetrahedron Lett. **1978**, 3527, and references cited therein.

(Received in USA 31 May 1984)